Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Scroll Top
One Allentown Parkway, Allen Texas 75002, USA

RX & Admin

Value-Added Benefits for Hospitals

The Quest MPS®3 ND technology can benefit hospitals at multiple levels through the next generation of myocardial protection. The advanced technology can reduce hospitals costs and simplify pharmacy management.

Benefits of Quest MPS technology that can improve the bottom line:

Improved Patient Outcomes

Proven to reduce adverse events with a faster recovery.

Patient Safety

The Quest MPS 3 ND System is a safe and reliable cardioplegia delivery system. With monitoring capabilities at the fingertips of the perfusionist, precision and accuracy are unmatched by any other system. For peace of mind, there is an internal backup battery in case of a facility power outage.

Data Collection

Key data is captured and stored on the controller. This information is available to further identify and evaluate trends for continuous improvement.

Reduce pharmacy and hospital costs2

Investing in the Quest MPS 3 ND System, hospitals can benefit by:

• Eliminating the purchasing of compound cardioplegia
• Reducing waste
• Improving patient outcomes

The innovative design of the Quest MPS 3 ND System allows drawing drugs directly from the vial, which eliminates the need for compounding multi-ingredient cardioplegia solutions and can reduce waste.

With the superior myocardial protection that microplegia offers using the Quest MPS Technology patients can benefit from a quicker recovery and less time in ICU.2

Microplegia with The Quest MPS System versus traditional cardioplegia

rx-2-1-100x100

Reduction
in adverse events

rx-5-100x100

Patients
1 day less

rx-6-100x100

Discharge
1 day earlier

rx-4-100x100

Reduction
in medication costs

rx-3-100x100

Reduction
in hospital costs

rx-1-1-100x100

Better
patient outcomes

Pharmacy Management and Data

In addition to eliminating the need for compounding cardioplegia drugs, the Quest MPS 3 ND System can assist with drug accuracy and tracking. Each individual case saves the protocols used during the procedure including drug lists and dosage amounts. The Quest MPS 3 ND System can interface directly with hospital files to assist with tracking and usage of drugs. The data from cases is downloadable via a removable flash drive that can be imported into a spreadsheet software.

The Quest MPS 3 ND System is more than a capital expenditure – it completes the cardiovascular team.

Want to Know More, or Schedule a Demo?

2 Marc W Gerdisch, et al. Clinical and economic benefits of advanced microplegia delivery system in cardiac surgery: evidence from 250 hospitals. Journal of Comparative Effectiveness Research 2018; April: 673-683